<DOC>
	<DOCNO>NCT00113386</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Cisplatin docetaxel may make tumor cell sensitive radiation therapy . Giving one drug ( combination chemotherapy ) together radiation therapy surgery may shrink tumor remove . Giving chemotherapy surgery may kill tumor cell remain surgery . It yet know whether give cisplatin docetaxel together radiation therapy effective give cisplatin together docetaxel treat non-small cell lung cancer . PURPOSE : This randomized phase III trial study cisplatin , docetaxel , radiation therapy see well work compare cisplatin docetaxel treat patient undergo surgery newly diagnose stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Cisplatin Docetaxel With Without Radiation Therapy Treating Patients Who Are Undergoing Surgery Newly Diagnosed Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare overall survival patient newly diagnose favorable prognosis stage IIIA non-small cell lung cancer treat neoadjuvant cisplatin docetaxel v without thoracic conformal radiotherapy follow surgical resection docetaxel . Secondary - Compare median progression-free survival patient treat regimen . - Compare clinical pathologic response rate patient treat regimen . - Compare toxicity regimens patient . - Correlate pathological complete response disease-free overall survival patient treat regimen . - Correlate DNA damage repair gene ( ERCC1 XRCC1 ) , microtubule-related protein ( TUBB-III MAP4 ) , shed tumor DNA response outcome patient treat regimen . - Correlate protein profile , use MALDI-TOF proteomic analysis tumor serum , response prognosis patient treat regimen . - Compare quality life patient treat regimen . - Determine efficacy fludeoxyglucose F 18 positron emission tomography scan assess pathological response tumor mediastinal lymph node predict long-term outcome patient treat regimen . - Correlate comorbid condition survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord T stage ( T1 vs T2-3 ) , number involve mediastinal lymph node ( 1 vs 2 v evaluable ) , nodal micrometastases vs clinically involve node ( mN2 v cN2 ) . - Induction therapy : Patients randomize 1 2 treatment arm . - Arm I : Patients receive cisplatin IV 1 hour docetaxel IV 1 hour day 1 22 . - Arm II : Patients undergo thoracic conformal radiotherapy daily 5 day week approximately 5½ week ( total 28 dos ) . Patients also receive cisplatin IV 1 hour day 1 , 8 , 22 , 29 docetaxel IV 1 hour day 1 , 8 , 15 , 22 , 29 . - Surgery : Within 4-8 week completion induction therapy , patient stable disease well undergo lobectomy pneumonectomy formal systematic mediastinal lymph node dissection . - Consolidation therapy : Beginning 4-6 week surgery , patient receive docetaxel IV 1 hour day 1 , 22 , 43 pegfilgrastim filgrastim ( G-CSF ) subcutaneously day 2 , 23 , 44 . Quality life assess baseline , within 2 week completion induction therapy , 6 12 month surgery . After completion study treatment , patient follow every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 574 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm primary nonsmall cell lung cancer ( NSCLC ) * , include follow cellular type : Adenocarcinoma Squamous cell carcinoma Large cell carcinoma Nonlobar nondiffuse bronchoalveolar cell carcinoma NSCLC otherwise specify NOTE : *Diagnosed within past 3 month ; diagnosis mediastinal nodal biopsy needle aspiration allow provide distinct lung primary ( separate node ) clearly evident CT scan Stage IIIA disease T1T3 disease If pleural effusion present , must meet ≥ 1 follow criterion exclude T4 disease : Pleural effusion cytologically negative thoracentesis Documented absence pleural metastasis pleural effusion cytologically negative thoracoscopy ( patient pleural effusion CT scan [ chest xray ] deem small tap safely either CT scan ultrasound guidance ) Confirmed positive ipsilateral mediastinal lymph node ( ) ( N2 disease ) ** , without positive ipsilateral hilar node , mediastinoscopy , mediastinotomy , endoscopic ultrasoundguided transesophageal biopsy , thoracotomy , videoassisted thoracoscopy , Wang needle , fine needle aspiration bronchoscopic CT guidance N2 node must separate primary tumor CT scan surgical exploration AND maximum diameter ≤ 3.0 cm Mediastinoscopy OR mean mediastinal lymph node biopsy require ( regardless primary tumor site ) patient subcarinal lymphadenopathy size criterion positron emission tomography ( PET ) scan If lymph node contralateral mediastinum neck visible contrast CT scan chest AND ≥ 1.0 cm OR contralateral involvement suggest PET scan , lymph node must confirm negative one diagnostic procedure AND N3 status must confirm negative histology cytology No palpable lymph node supraclavicular area higher neck unless proven benign excisional biopsy A nodal biopsy needle aspiration may omit provide follow criterion true : Paralyzed leave true vocal cord bronchoscopy indirect laryngoscopy Nodes visible aortopulmonary window ( level 5 ) region CT scan Distinct primary tumor ( separate node ) visible CT scan No evidence subcarinal nodal involvement CT scan NOTE : **PET scan positivity sufficient establish N2 nodal status Measurable disease chest xray and/or contrastenhanced CT scan Candidate surgery Resectable disease No distant metastasis , include ipsilateral contralateral parenchymal lesion liver adrenal metastasis , history physical examination , fludeoxyglucose F 18 PET scan , MRI CT scan brain , chest xray and/or CT scan lung upper abdomen PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,800/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10.0 g/dL ( transfusion intervention allow ) Hepatic ALT AST ≤ 2.5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Bilirubin ≤ 1.5 time ULN No hepatic insufficiency result clinical jaundice coagulation defect Renal Creatinine clearance ≥ 60 mL/min Cardiovascular No unstable angina congestive heart failure require hospitalization within past 6 month No transmural myocardial infarction within past 6 month Pulmonary FEV_1 ≥ 2.0 L OR Predicted postresection FEV_1 ≥ 0.8 L DLCO ≥ 50 % predict No chronic obstructive pulmonary disease exacerbation No respiratory illness require hospitalization would preclude study therapy Immunologic No AIDS No prior allergic reaction study drug No history severe hypersensitivity drug formulate polysorbate 80 No acute bacterial fungal infection require IV antibiotic Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No unintentional weight loss &gt; 5 % body weight within past 6 month No preexist peripheral neuropathy ≥ grade 2 No invasive malignancy within past 3 year except nonmelanoma skin cancer carcinoma situ breast , oral cavity , cervix No severe active comorbidity PRIOR CONCURRENT THERAPY : Biologic therapy No prior biological agent cancer No concurrent filgrastim ( GCSF ) , sargramostim ( GMCSF ) , pegfilgrastim study induction therapy ( patient randomize chemoradiotherapy arm ) Chemotherapy No prior systemic chemotherapy cancer Prior chemotherapy different cancer allow Endocrine therapy Not specify Radiotherapy No prior radiotherapy region cancer would result overlap radiotherapy field No routine postoperative radiotherapy No concurrent intensity modulate radiotherapy Surgery See Disease Characteristics Other No prior gefitinib cancer No concurrent amifostine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>